Check out our new AlphaBind preprint, out today on bioRxiv, demonstrating our industry-leading antibody optimization model! We are also excited to share that we have recently measured our BILLIONTH protein-protein interaction with AlphaSeq, providing the crucial training data to predict protein binding. Preprint: https://lnkd.in/gT-96Va8 Blog post: https://lnkd.in/gwdQKgYc The AlphaBind model is built on top of NVIDIA BioNemo and this was a wonderful team effort between the two companies. Special thanks to Aditya Agarwal, James Harrang, David Noble, Kerry McGowan, Adrian Lange, Ryan Emerson, and Xin Yu.
关于我们
A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/
- 网站
-
https://www.aalphabio.com/
A-Alpha Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Seattle,Washington
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Drug discovery、Protein Engineering、Synthetic Biology、Immunocytokines、Molecular Glues、Oncology和Protein-protein interactions
地点
-
主要
2101 4th Ave
Fifth Floor
US,Washington,Seattle,98121
A-Alpha Bio员工
动态
-
Congratulations to David Baker, A-Alpha Scientific Advisor and AlphaSeq Co-Inventor, on winning the 2024 Nobel Prize in Chemistry! This is a much deserved recognition of David's incredible contributions to protein structure prediction and design - and the impact of the work coming out of the Institute for Protein Design, University of Washington. Congratulations as well to Google Deepmind's Demis Hassabis and John M. Jumper! https://lnkd.in/ewJJssDY
-
Now hiring for a Research Associate I on our Technical Operations team! Come join A-Alpha Bio on our quest to improve human health! Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/gcQJaUmd
-
Now hiring for a Research Associate II on our Technical Operations team! Come join A-Alpha Bio on our quest to improve human health! Check out the job description and application linked here - we're looking forward to seeing your applications! https://lnkd.in/g6myFfXB
-
Now hiring for a Director of Communications! Come join A-Alpha Bio on our quest to improve human health! This person will lead all corporate communications functions - fostering external understanding of our platforms, therapeutic programs,?corporate strategy, and?industry partnerships. If you know of someone that may be a great fit, please reach out! https://lnkd.in/gAQRmDg6
Careers
aalphabio.com
-
Now hiring for a Scientist I on our Platform R&D team! Come join A-Alpha Bio on our quest to improve human health! This person will design, execute, and analyze experiments that leverage our AlphaSeq and?AlphaBind?platforms for drug discovery, with a focus on biologic therapeutics. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g4duQ2iU
-
We are excited to share that A-Alpha Bio has been awarded an additional $14.5M from the United States Department of Defense to enable machine learning models that rapidly predict treatments against possible biological threats. Funding from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND will expand our partnership with Lawrence Livermore National Laboratory (LLNL) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) program. This announcement follows two years of successful collaboration between A-Alpha and LLNL – beginning with coronaviruses and expanding to multiple undisclosed pathogen families of concern – in which A-Alpha’s AlphaSeq data has been used to train ML models that predict antibody-antigen binding. We look forward to continuing and expanding the partnership! Read more in today's press release: https://lnkd.in/eVKne9eE And thanks to Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD for a great piece: https://lnkd.in/eXB-mufW
-
Now hiring for a Process Engineer I! Come join A-Alpha Bio on our quest to improve human health! This person will serve as a bridge between our Technical Operations and R&D organizations to improve efficiency and quality, troubleshoot existing processes, and facilitate the transition of new processes. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g38XNqQX
Careers
aalphabio.com
-
Now hiring for a Scientist I, Antibody Discovery! Come join A-Alpha Bio on our quest to improve human health! This person will join our Biologics Discovery team to execute and optimize antibody discovery and assay development initiatives. If you know of someone that may be a great fit, please reach out! https://lnkd.in/g49BJ2r7
Careers
aalphabio.com
-
A-Alpha Bio转发了
I'm looking forward to attending and presenting at Life Science Innovation Northwest this Thursday! This is one of my favorite annual meetings - a great opportunity to catch up with the local PNW biotech community, which has become more and more vibrant over the eight years I've been attending. I'll be giving an update on what we've been up to at A-Alpha Bio and I'm excited to hear about the new innovations, recent deals, and emerging companies in our region. I hope to see you there!